Surgery Partners (NASDAQ:SGRY) Insider Danielle Burkhalter Sells 3,469 Shares

Surgery Partners, Inc. (NASDAQ:SGRY) insider Danielle Burkhalter sold 3,469 shares of the company’s stock in a transaction on Friday, March 13th. The stock was sold at an average price of $12.83, for a total value of $44,507.27. Following the completion of the sale, the insider owned 76,864 shares of the company’s stock, valued at $986,165.12. This trade represents a 4.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Danielle Burkhalter also recently made the following trade(s):

• On Friday, March 6th, Danielle Burkhalter sold 7,736 shares of Surgery Partners stock. The stock was sold at an average price of $13.60, for a total value of $105,209.60.

Surgery Partners Stock Performance

NASDAQ SGRY traded up $0.01 on Monday, hitting $12.39. 1,509,638 shares of the company traded hands, compared to its average volume of 1,747,282. The business’s 50 day moving average price is $14.95 and its 200-day moving average price is $17.72. Surgery Partners, Inc. has a 52-week low of $12.25 and a 52-week high of $24.60. The company has a current ratio of 1.87, a quick ratio of 1.71 and a debt-to-equity ratio of 1.15. The company has a market capitalization of $1.60 billion, a price-to-earnings ratio of -19.98 and a beta of 1.95.

Surgery Partners (NASDAQ:SGRY) last issued its quarterly earnings results on Monday, March 2nd. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.19). Surgery Partners had a positive return on equity of 1.28% and a negative net margin of 2.35%.The company had revenue of $885.00 million during the quarter, compared to analysts’ expectations of $866.54 million. During the same quarter in the previous year, the company earned $0.44 EPS. The business’s quarterly revenue was up 2.4% compared to the same quarter last year. Equities analysts expect that Surgery Partners, Inc. will post 0.67 earnings per share for the current year.

Surgery Partners declared that its Board of Directors has initiated a share buyback plan on Thursday, February 26th that authorizes the company to buyback $200.00 million in shares. This buyback authorization authorizes the company to purchase up to 9.7% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s management believes its stock is undervalued.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Hsbc Holdings PLC boosted its stake in Surgery Partners by 104.2% in the 4th quarter. Hsbc Holdings PLC now owns 1,931,577 shares of the company’s stock worth $30,151,000 after purchasing an additional 985,748 shares during the period. Alpine Global Management LLC bought a new stake in shares of Surgery Partners during the fourth quarter valued at approximately $175,000. Empowered Funds LLC raised its position in shares of Surgery Partners by 1,340.9% during the fourth quarter. Empowered Funds LLC now owns 161,419 shares of the company’s stock valued at $2,494,000 after buying an additional 150,216 shares during the last quarter. One68 Global Capital LLC purchased a new position in shares of Surgery Partners in the fourth quarter worth $371,000. Finally, Man Group plc purchased a new position in shares of Surgery Partners in the fourth quarter worth $5,080,000.

Wall Street Analyst Weigh In

A number of research firms have commented on SGRY. Royal Bank Of Canada decreased their target price on shares of Surgery Partners from $31.00 to $20.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 4th. UBS Group reissued a “buy” rating on shares of Surgery Partners in a research note on Wednesday, March 11th. Mizuho decreased their price objective on shares of Surgery Partners from $19.00 to $17.00 and set an “outperform” rating on the stock in a research report on Thursday, March 5th. Jefferies Financial Group restated a “buy” rating on shares of Surgery Partners in a research note on Wednesday, March 4th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Surgery Partners in a report on Monday, December 29th. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Surgery Partners currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.36.

About Surgery Partners

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.